Zydus Lifesciences ropes in Tushar Shroff as President-Finance

Published On 2025-05-01 09:00 GMT   |   Update On 2025-05-01 09:00 GMT
Advertisement

Gujarat: Zydus Lifesciences has announced the appointment of Tushar Shroff as a President-Finance.

"This is to inform that based on the recommendation of Nomination and Remuneration Committee, the Board of Directors of Zydus Lifesciences Limited have approved the appointment of Mr. Tushar Shroff as a President-Finance, who shall form part of the Senior Management Personnel," Zydus informed in a BSE filing.

Advertisement
Tushar Shroff, aged 55 years, is a Chartered Accountant and a Cost Accountant. He has 29+ years’ post qualification experience, out of which 20 years’ experience is in pharma industry. In pharma industry, he has experience in managing pharmaceutical life cycle of small, large molecules, blood products, from innovation to late life cycle development of generic, branded generic, CDMO and OTC business for USA, EU, and pharma emerging markets.
Out of 29 years, he has 15+ years’ experience as a chief financial officer. He has domain knowledge in the areas of business partnering, operational finance, corporate finance, mergers and acquisitions, divestures, in / out licensing, treasury management and fund raising, investor relations, strategic finance (structuring and re-organisation), legal, secretarial and information technology. Amongst others, he has worked with ABB Limited, Piramal Healthcare Limited and
IntasPharmaceuticals Limited
.
He had also worked with Zydus Lifesciences Limited from December 2010 to January 2019. Before joining Zydus, he was the Chief Financial Officer at Sterlite Technologies Limited.

Read also: Zydus Lifesciences inks pact with PAI Partners, other shareholders to buy majority stake in Amplitude Surgical SA

Zydus Lifesciences Ltd. is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group has a significant presence in cancer related therapies and offers a wide range of solutions with cytotoxic, supportive & targeted drugs.

Read also: Zydus Medtech, Braile Biomedica of Brazil ink global licensing pact to commercialise TAVI technology

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News